بررسی اثر درمانی پیوند سلول های بنیادی مزانشیمی آمنیونی در درمان دیابت نوع یک

نوع مقاله: مقاله پژوهشی

نویسندگان

1 دانشجوی دکتری بیوتکنولوژی پزشکی، دانشگاه علوم پزشکی ایران، تهران، ایران

2 مرکز تحقیقات سلولی و مولکولی، دانشگاه علوم پزشکی یاسوج، یاسوج، ایران

3 دکتری حرفه ای دامپزشکی، دانشگاه آزاد اسلامی واحد کرج، کرج، ایران.

چکیده

دیابت قندی می­تواند ناشی از فقدان انسولین یا مقاومت بافت­های محیطی به انسولین همراه با کاهش ترشح انسولین باشد. مطالعه حاضر با هدف بررسی اثر درمانی پیوند سلول­های بنیادی مزانشیمی آمنیونی دردرمان دیابت نوع یک صورت گرفت این مطالعه از نوع تجربی بوده وحیوانات به چهار گروه تقسیم شدند: گروه شاهد یا سالم، گروه کنترل دیابتی، گروهی که سلول­ها را به همراه محیط کشت دریافت کردند و گروهی که فقط سوپ سلولی دریافت کردند. سطوح قند و انسولین خون و وزن حیوانات در طول مطالعه با آزمون های آماری ANOVA و t-test بررسی شدند. با پیوند مرحله اول سلول های بنیادی کاهش معنی داری در قند خون حیوانات هر دو گروه دریافت کننده سلول به همراه محیط کشت (004/0=p ) و گروهی که سوپ سلولی دریافت کرده بودند (014/0=p ) نسبت به گروه کنترل وجود داشت. این نتایج پس از مرحله دوم مشاهده نشد. سطوح انسولین اختلاف معنی­داری به لحاظ آماری نداشت. مطالعه حاضر نشان داد که پیوند مکرر سلول­های بنیادی مزانشیمی می­تواند قند خون را کاهش داده و سطح انسولین خون را بالا ببرد و تزریق سوپ سلولی به تنهایی نمی­تواند به اندازه پیوند سلول موثر باشد.

کلیدواژه‌ها


عنوان مقاله [English]

The Therapeutic Effect of Amniotic Mesenchymal Stem Cell Transplantation in Type-1 Diabetes

نویسندگان [English]

  • Soosan Rostam Pur 1
  • Yadolah Edalat panah 2
  • Fariba Enayati parvar 2
  • Reza Haghighi 3
1 Department of Medical Biotechnology, Iran University of Medical Sciences, Tehran, Iran
2 Cellular and Molecular Research Center, Yasouj University of Medical Sciences, Yasuj, Iran
3 Veterinary, Karaj Branch, Islamic Azad University, Karaj, Iran
چکیده [English]

Diabetes mellitus can occur due to insulin deficiency or environmental tissues resistance to insulin with the reduction of insulin secretion. The present study aimed to investigate the therapeutic effect of amniotic mesenchymal stem cell transplantation in the treatment of type 1 diabetes.  This study was of experimental type and the animals were divided into four groups including the control or healthy, the diabetic control group, the group receiving cells with the medium, and the group receiving only supernatant soup. Glucose and blood insulin levels and animal weight were studied by ANOVA and t-test during the study. With the first stage of stem cell transplantation, a significant reduction was found in the animal blood glucose of both groups receiving cell and medium (p = 0.004) and the group receiving supernatant soup (p = 0.014) than the control group. Such results were not observed after the second stage. The insulin levels had no statistically significant difference. The present study indicated that the repeated transplantation of Amniotic Mesenchymal stem cells can decrease the blood glucose but increase the blood insulin level and the injection of supernatant soup alone be solely effective as much as the cell transplantation.

کلیدواژه‌ها [English]

  • Stem cell transplantation
  • Amnion
  • Type-1 diabetic model
  • Diabetes treatment

Aali E., 2014. A comparative study of mesenchymal stem cell transplantation with its paracrine effect on control of hyperglycemia in type 1 diabetic rats. Journal of Diabetes & Metabolic Disorders, 13(1): 76-85.

2. Bassi E.J., 2012. Immune regulatory properties of allogeneic adipose-derived mesenchymal stem cells in the treatment of experimental autoimmune diabetes. Journal of Diabetes, 61(10): 2534- 2545.

  1. Biessels G.J., Kerssen A., De Haan E.H., Kappelle, L.J., 2007. Cognitive dysfunction and diabetes: implications for primary care. Primary Care Diabetes, 1(4): 187-189.
  2. Bouwens L, Houbracken I, Mfopou J.K., 2013. The use of stem cells for pancreatic regeneration in diabetes mellitus. Nature Revews Endocrinology, 9(10):598-606.
  3. Bruns H., 2013. Alternatives to islet transplantation: future cell sources of beta-like cells. Clinical Transplantation, 25(6): 30-33.
  4. Ding Y., 2010. Mesenchymal stem-cell immunosuppressive capabilities: therapeutic implications in islet transplantation. Clinical Transplantation, 89(3): 270-273.
  5. Ezquer F.E., Ezquer M.E., Parrau D.B., Carpio D., Yanez A.J., Conget P.A., 2008. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. American society for blood and marrow transplantation, 14: 631-640.
  6. Favaro E., 2014. Human mesenchymal stem cell - derived microvesicles modulate T cell response to islet antigen glutamic acid decarboxylase in patients with type 1 diabetes. Diabetologia, 57(8): 1664-1673.
  7. Fiorina P., 2009. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. Journal of Immunology, 183(2): 993-1004.
  8. Hatziavramidis D.T., Karatzas T.M., Chrousos G.P., 2013. Pancreatic islet cell transplantation: an update. Annals Biomedical Engineering, 41(3): 469-476.
  9. Jacobson M.D., Raff M.C., 1995. Programmed cell death and Bcl-2 protection in very low oxygen. Journal of Nature, 374(6525): 814-816.
  10. Karnieli O., 2007. Generation of insulin-producing cells from human bone marrow mesenchymal stem cells by genetic manipulation. Stem Cells, 25(11): 2837-2844.
  11. Kota D.J., 2013.  TSG-6 produced by hMSCs delays the onset of autoimmune diabetes by suppressing Th1 development and enhancing tolerogenicity. Journal of Diabetes, 62(6): 2048-2058.
  12. Li Y.Y., 2012. Adipose-derived mesenchymal stem cells ameliorate STZ-induced pancreas damage in type 1 diabetes. Biomed Materials Engineering, 22(1-3): 97-103.
  13. Lin H.Y., 2010. Fibronectin and laminin promote differentiation of human mesenchymal stem cells into insulin producing cells through activating Akt and ERK.  Journal of Biomedical Science, 17(4): 56-65.
  14. Marzo I., Brenner C., Kroemer G., 1998. The central role o- mitochondrial megachannel in apoptosis: evidence obtained with intact cells, isolated mitochondia, and purified protein complexes. Journal of Biomedical pharmacother, 52(6): 248-251.
  15. Miszta-Lane H., 2006. Stem cell sources for clinical islet transplantation in type 1 diabetes: embryonic and adult stem cells. Medical Hypotheses, 67(4): 909-913.
  16. Mundre V., 2013. Mesenchymal stem cell-based therapy. Molecular Pharmaceutics, 10(1): 77-89.
  17. Nadri S., Soleimani M., 2007. Comparative analysis of mesenchymal stromal cells from murine bone marrow and amniotic fluid. Journal of Cytotherapy, 9(8):729-737.
  18. Neshati Z., 2010.  Differentiation of mesenchymal stem cells to insulin-producing cells and their impact on type 1 diabetic rats, Journal of Physiology Biochemestry, 66(2): 181-187.
  19. Ngoc P.K., 2011. Improving the efficacy of type 1 diabetes therapy by transplantation of immunoisolated insulin-producing cells. Human Cell, 24(2): 86-95.
  20. Sreemantula S., Kilari E.K., Vardhan V.A., Jaladi R., 2005. Influence of antioxidant (L-ascorbic acid) on tulbotamide induced hypoglycaemia/ antihyperglycaemia in normal and diabetic rats. BMC Endocrine Disorders, 5(1): 2-5.
  21. Urban V.S., Kiss J., Kovacs J., Gocza E., Vas V., Monostori E., Uher F., 2008. Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells, 26: 244-253.

Zanone M.M., 2010. Human mesenchymal stem cells modulate cellular immune response to islet antigen glutamic acid decarboxylase in type 1 diabetes. The Journal of Clinical Endocrinology Metabolism, 95(8): 3788-3797.